Estimating the cost of strategic entry delay in pharmaceuticals : the case of Ambien CR
Year of publication: |
September 2016
|
---|---|
Authors: | Shapiro, Bradley T. |
Published in: |
Quantitative marketing and economics : QME. - Dordrecht [u.a.] : Springer Science + Business Media, ISSN 1570-7156, ZDB-ID 2114104-6. - Vol. 14.2016, 3, p. 201-231
|
Subject: | Pharmaceutical innovation | Entry | Regulation | Advertising | Markteintritt | Market entry | Pharmaindustrie | Pharmaceutical industry | Arzneimittel | Pharmaceuticals | Werbung | Regulierung | Innovation | Pharmakologie | Pharmacology | Arzneimittelmarkt | Pharmaceutical market |
-
Unpacking the effects of adverse regulatory events : Evidence from pharmaceutical relabeling
Higgins, Matthew J., (2021)
-
Do cost-sharing and entry deregulation curb pharmaceutical innovation?
Grossmann, Volker, (2013)
-
The impact of the entry of biosimilars : evidence from Europe
Scott Morton, Fiona, (2017)
- More ...
-
Cockburn, Iain M., (2013)
-
TV Advertising Effectiveness and Profitability : Generalizable Results From 288 Brands
Shapiro, Bradley T., (2021)
-
Aitken, Murray L., (2018)
- More ...